OVERVIEW

The American Society for Preventive Cardiology (ASPC) 2021 Virtual Summit on CVD Prevention is organized by The American Society for Preventive Cardiology (ASPC) and will be held from Jul 23 - 25, 2021.

Target Audience:
This activity is designed for an audience of physicians, physician assistants, nurses, pharmacists, dieticians, research scientists and other healthcare professionals.

Accreditation:
Physicians:
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Designation Statement:
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 15.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Summit Overview:
The ASPC 2021 Congress on CVD Prevention will be converted to 100% virtual this summer. The ASPC online scientific sessions will aim to bring attendees the same learning and connection they find at our face-to-face meeting. This year we will emphasize inclusiveness and the care of one and all at risk for cardiovascular disease. The program will provide cutting-edge lectures, lively debates, and practical applications. We will explore the broad spectrum of preventive cardiology led by world-renown Experts in the field. It will cover topics such as Emerging Therapies for Lipid Management, CAC vs. biomarkers, Chest pain guidelines and Imaging, Prevention of Heart Failure, Atrial Fibrillation, PAD evaluation, treatment, and management, practical application of New Prevention Therapies, CVD prevention in Special populations, and more.

Learning Objectives:
Upon completion of the educational activity, participants should be able to:
• Evaluate emerging lipid therapies and assess their ASCVD risk reduction while implementing this knowledge into clinical practice.
• Evaluate the literature involving CVD risk in CKD and DM patients in an effort to implement this knowledge into clinical practice.
• Compare the literature involving biomarkers versus CAC testing in ASCVD prevention and implement this knowledge into clinical practice.
• Assess and evaluate current ACS treatment strategies in patients with COVID-19 and implement into daily management.
• Review and assess chest guidelines and understand the diagnosis and management of patients presenting with chest pain utilizing new diagnostic clinical algorithms.
• Evaluate the latest literature to determine the pretest probability (PTP) of coronary artery disease (CAD) in symptomatic patients and how to proceed with test selection and implement this knowledge into clinical practice.
• Evaluate the literature involving diets to reduce cardiovascular risk and implement this knowledge into clinical practice.
• Evaluate the literature involving lifestyle modifications to prevent heart failure and implement this knowledge into clinical practice.
• Understand strategies to prevent atrial fibrillation and implement this knowledge into clinical practice.
• Evaluate the medical and lifestyle management of PAD that incorporate therapies to improve functional outcomes, reduce adverse cardiovascular, and limb events.
• Understand implementation strategies to improve care, prevent heart disease, and implement this knowledge into clinical practice.
• Evaluate best practices in telemedicine, including proper billing, and implement this knowledge into clinical practice.
• Evaluate the literature involving transgender patients, CVD, and hormone replacement therapy and implementing this knowledge into clinical practice.
• Discuss current strategies to prevent heart disease, stroke, and diabetes through proper diet and accessibility and implement this knowledge into clinical practice.
• Evaluate the literature involving the unmet needs in the use of statins and aspirin in PLWHIV and review the incompleteness of the current guideline to implement any prevention knowledge into clinical practice.
• Evaluate the clinical data involving elevated cholesterol in patients less than 40 and implement prevention strategies into clinical practice.